P3.14. A NOVEL ANTI-INFLAMMATORY COMPOUND REDUCE ASTROCYTIC ACTIVATION IN FIBRILLAR MODEL OF PARKINSON'S DISEASE.
Katarzyna Maziarz1, Justyna Barut1, Maciej Degutis1, Piotr Chmielarz1, Ryszard Bugno2, Grzegorz Kreiner1
1 Maj Institute of Pharmacology Polish Academy of Sciences, Department of Brain Biochemistry, Smętna 12 Str, 31-343 Kraków, Poland
2 Maj Institute of Pharmacology Polish Academy of Sciences, Department of Medicinal Chemistry, Smętna 12 Str, 31-343 Kraków, Poland
INTRODUCTION: Epidemiological studies suggest that chronic use of NSAIDs may reduce the risk of developing Parkinson’s disease (PD), likely through modulation of neuroinflammatory processes. However, their application for long-term treatment in PD would likely require sustained high-dose regimens, raising safety concerns. MIP001 is a novel anti-inflammatory compound with an excellent safety profile and therapeutic efficacy.
AIM(S): The aim of this preliminary study was to evaluate the potential of MIP001 to modulate neuroinflammation in PD-relevant in vitro models.
METHOD(S): Primary mouse astrocyte cultures were treated with fibrillar α-synuclein (PFF) and MIP001 at a concentration of 10 μM, followed by immunofluorescent staining, microscopic evaluation, and measurement of IL-1β, IL-6, and TNFα levels in the culture medium.
RESULTS: MIP001 reversed the morphological changes in astrocytes induced by PFF and pro-inflammatory cytokines (immunofluorescence analysis). It also significantly reduced the production of TNFα (p < 0.05) by activated astrocytes, without affecting cell viability.
CONCLUSIONS: These preliminary data demonstrate the capability of MIP001 to modulate neuroinflammation in PD-relevant models, supporting further investigation into its neuroprotective potential in more complex systems, as well as detailed mechanistic studies.
FINANCIAL SUPPORT: The study was supported by a programme coordinated by the Medical Research Agency, co-financed by the European Union under the NextGeneration EU initiative, within the framework of the National Recovery Plan, Component D, Investment D3.1.1 (project no. 2024/ABM/03/KPO/KPOD.07.07-IW.07-0173/24-00).